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Diagnosing And Managing
Panic Disorder In Primary Care
K Y Mak,* MBBS, DPM, MD, FRCPsych.
Department of Psychiatry
The University of Hong Kong
Summary
Panic disorder is a common and frightening disorder, but it is often under-diagnosed and under-treated. It has
a high morbidity and mortality including suicide. The causes are multi-factorial, both biological and psychosocial.
Co-morbidities include agoraphobia, other anxiety disorders, depressive disorder and substance abuse. A diagnosis
checklist is suggested. Management using medications and/or cognitive-behavioural therapy is not difficult and
relatively safe. Prompt recognition and treatment can have a gratifying response and good prognosis. (HK Pract
1999;21:417-424)
***
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Introduction
Up to a t h i r d of p e o p l e
experience episodes of panic when
under stress, such as being chased by
a dog. This usually lasts less than 20
minutes, occurs mostly at day time,
and when away from home. Up to
25% of sufferers also have 'nocturnal
panics' and wake up with panicky
feelings or thoughts, not related to
bad dreams.1 Such attack is similar
to other anxie ty states such as
extreme stage fright, but it differs
from anxiety in that a panic victim
feels better when with other people
and worse when left alone. Even
then, isolated attack does not amount
to a genuine panic disorder.
If the attacks occur frequently, it
becomes a panic disorder, which is
also fairly common. It is estimated
that 7% of the population in the
United States have recurrent panic
attacks, and 3% of them have attacks
frequently enough to be classified as
suffering from panic disorder.
Panic disorder is often under-
diagnosed by doctors in primary care.
However, it is a distressing life-time
disorder with recurrences. The
sufferers may receive unnecessary
medical tests and hospitalisations. If
untreated, the disorder carries a
significant morbidity (e.g. become
home-bound) and mortality from
suicide.2
Epidemiology
The life-time prevalence rate is
1-3%. The female to male ratio is 3
to 1 for those with co-existing
agoraphobia (as the males may be
forced to face the stressful situation),
but this sex difference is less marked
for those without agoraphobia. There
is no ethnic or racial difference. The
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age of onset is usually in the mid-20s.
It is uncommon after 40 and becomes
rare after 60 years of age.
Clinical features
Firstly, panic attack is defined as
"an unexpectedly, overwhelming
anxiety, intense short episodes of fear
of impending death or catastrophe,
e.g. a heart attack, a stroke or going
crazy".
For a panic disorder, there must
be some distressing somatic and/or
psychological symptoms (Table 1).
D u r i n g the a t tack , the ab i l i t y to
reason is d i s r u p t e d , the urge to
escape is overwhelming, and r isky
behaviour such as abruptly stopping
the car and leaving the scene may
r e s u l t . In be tween a t t acks the
su f f e r e r o f t en deve lops v a r y i n g
degrees of nervousness and apprehen-
sion, and becomes more irritable and
restless and preoccupied about future
attacks (fear of the panic). Some
even develop an avoidant behaviour
(Table 2) and they may f i n a l l y
become housebound.
There are o f t e n o ther co-
m o r b i d i t i e s w h i c h i n c l u d e t h e
following:
1. Nearly three-quarter of patients
suffering from agoraphobia (fear
of being in a place from which
escape might be diff icul t) have
panic disorder.
2. About 50% of panic patients have
other anxie ty disorders, e.g.
soc ia l p h o b i a s , obse s s ive -
compulsive disorder, generalized
anxiety disorder.
Table 1: Checklist for panic disorder
A. Have you unexpectedly (i.e. without any overt cause)
experienced a recent attack of overwhelming anxiety,
with the following features?
1. Shortness of breath or smothering
2. Dizziness, faintness, unsteadiness, or lightheadness
3. Increased heart rate or pounding heart
4. Trembling or shaking
5. Feeling of choking
6. Sweating
7. Abdominal distress or nausea
8. Feeling that one's surroundings are not quite real
or feeling that oneself is not real
9. Feelings of numbness or tingling sensations
10. Hot flushes or chills
11. Chest pain or discomfort
12. Fear of dying
13. Fear of losing control or going crazy
Total
B. How often is your attack?
1. Once only
2. More than once
3. Approximately how many attacks in the past month?
o
O
O
a
a
a
O
Yes
Yes
Yes
Yes
Yes
Yes
Yes
O
a
a
a
a
O
a
No
No
No
No
No
No
No
O
O
a
a
a
a
Yes
Yes
Yes
Yes
Yes
Yes
O
O
a
a
a
a
No
No
No
No
No
No
Yes
Yes
O No
a NO
C. Following the above attack(s), have you experienced
(for a month or more) the following features?
1. Persistent concern about further attacks
2. Worry about the implications or consequences
3. A change in behaviour due to the attacks*
D. Have you any significant physical problems such as
hyperthyroidism, addiction to coffee or strong tea etc.?
If yes, please specify the condition(s):
Yes
Yes
Yes
Yes
O No
d No
C5 No
No
* Examples of change in behaviour: avoid or restrict going outside the home alone e.g. going to
crowded places, standing in a line, travelling in a bus or a train etc. (agoraphobia)
N.B.: It needs a "yes" score of at least 4 items in A, a "yes" score for B-2. any "yes" score for C but
a "no" for D to qualify for a panic disorder.
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About 50% of panic pat ients
have an affective disorder such as
depressive illness.
About 20% of panic patients have
abuse of a l coho l or d r u g s .
Perhaps initially these are taken
to calm the panics.
Some patients with somatoform
disorder and hypochondriasis also
have panic disorder.
Diagnosis
According to the DSM(IV) of
t h e A m e r i c a n P s y c h i a t r i c
Associa t ion , a panic disorder is
diagnosed when there are recurrent
unexpected attacks, and at least one
of the following which lasts for 1
month or more:
a. persistent concern about further
attacks
b. worry about the implications of
the attack or its consequences
(Table 3)
c. significant change in behaviour
as a result of the attacks.
In addition, during the attack, at
least four of the symptoms in the
checklist (Table 1), must be present.
Those with less than four symptoms
are ca l led ' l i m i t e d s y m p t o m s '
attacks. Furthermore, such distress
must not be due to:
a. o r g a n i c cause , e .g. h y p e r -
thyroidism, caffeine; or
b. overt cause, e.g. exposure to
anxiety provoking situation.
Table 2: Some common forms of avoidant behaviour in panic
disorder
1. Avoid travelling (especially by plane) :
2. Avoid leaving home (or to places far from home)
3. Avoid lonely places (especially in tunnels)
4. Avoid driving on highways (especially to distant places)
5. Avoid going out alone (even to supermarkets)
6. Unease while waiting :
7. Unease standing in queues
Table 3: Some common cognitive thoughts in panic disorder
1. I am going to die
2. I am going to have a heart attack or stroke
3. I am going to faint
4. I must have a brain tumour
5. I must have some incurable disease
6. I am going crazy :
7. I will loose my self-control '. ' • •
8. I will act very foolishly
9. I will be paralysed
10. I am going to scream
Etiology
There are different etiological
factors, viz.:
Biological factors
Panic disorder is caused by a
super-sensit ive suffocat ion alarm
s y s t e m 3 due to a u t o n o m i c o r
adrenergic overactivity in the locus
coruleus, the limbic system and the
f r o n t a l co r t ex . The inc reased
catecholamines produce excessive
activity of the autonomic nervous
system. This causes hyperventilation
a n d a l k a l o s i s , w h i c h f u r t h e r
aggravate the panic. Some postulate
a genetic cause for this disorder, and
some suggest the involvement of the
neurotransmitter cholecystokinine 3.
Psychological factors
There are d i f fe ren t psycho-
logical theories including Freud's
u n c o n s c i o u s s e x u a l i m p u l s e s
threatening to burst into conscious-
ness and the classical conditioning
and learning theories. However, the
c u r r e n t one i s t he c o g n i t i v e -
behavioural theory by Clark4 who
proposed that there is a cognitive
misinterpretation of bodily sensations
as signs of catastrophe or imminent
danger (Figure 1). Such thoughts are
o f t e n t r a c e a b l e t o p r e v i o u s
e x p e r i e n c e s such as as thma in
childhood, or witnesses of death, etc.
Social factors
P a n i c d i s o r d e r i s o f t e n
precipitated by stressors such as
gains or losses in family, work or
finance and health problem.
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Perhaps it is a combination of
various factors that produce the
disorder. This means panic disorder
is a bio-psycho-social disorder, and
should be managed accordingly.
Management
General measures
Before treatment, the patient
should be assessed objectively (see
Table 4).
Some basic medical work-up
should be done to ru le out any
organic causes such as hyperthy-
roidism and cardiovascular disease.
In treatment, the patient should
be reassured of the relative benign
nature of panic attacks. Secondly,
there should be modification of any
stressors (e.g. ma r i t a l p roblem) .
Sometimes .it is a s sur ing to the
patient if the panic attack can be
demonstrated by the hyperventilation
test, which can be relieved by
controlled breathing exercises (8 slow
brea ths per m i n u t e e i t h e r by
abdominal breathing or by using a
paper bag). In the past, panic
disorder was induced by lactate
infusion, but only about 50% of the
patients showed a positive response.
Psycho-educa t ion on p a n i c
disorder using pamphlets is useful.
Figure 1: A cognitive model of panic attacks
Trigger stimulus (internal or external)
Perceived threat
Interpretation of
sensations as
catastrophic
Apprehension
Body
sensations
Table 4: Assessment of panic disorder
l. Date and time of the attacks. .."']') i';'-': ':.'•'.''Kl:\i-'-' •
2. Circumstances of the attacks - including places, whether alone
or accompanied, and what sort of activity at that period expected
or unexpected.
3. Duration of the attack.
4. The physical sensations, the psychological feelings and thoughts,
and the Behaviour in response to the attack.
5. The outcome of the attack, especially any avoidant behaviour,
both short term and long term.
This can instruct the patients how to
s t ay ca lm u s i n g d i s t r a c t i o n ,
relaxation and rational thinking, and
how to cope with stress with life-
style adjustment, time management,
adequate nutrition, exercise and rest.
Pharmacotherapy
Medica t ions can be used to
block the major or minor panic at-
tacks (Table 5). Many conventional
psychotropic drugs are useful. These
i n c l u d e b e n z o d i a z e p i n e s (e.g.
alprazolam, clonazepam), tricyclics
(e.g. imipramine, clomipramine) and
the monoamine oxidase inhibitors,
( M A O I s ) e . g . p h e n e l z i n e .
O c c a s i o n a l l y , p-blockers (e .g .
propranolol) and anticonvulsants (e.g.
valproate, carbamazepine) have also
been advocated. Most recently, the
newer selective serotonin re-uptake
i n h i b i t o r s ( S S R I s ) have been
advocated, i n c l u d i n g f luoxet ine , 5
fluvoxamine,6 paroxetine,7 sertraline
in ei ther fixed dosage8 or f lexible
dosage9 and citalopram.10 However,
con t ro l l ed t r a i l s of the th i rd
generation anti-depressants (such as
n e f a z o d o n e , v e n l a f a z i n e ,
mirtazapine) for panic disorder would
soon be reported.
The recommended dosage for
benzodiazepines appears alarming,
but studies showed that cure, not just
for symptomatic anxiety relief, is
possible only at h igh doses.11-12
However, the starting dose can be
low to avoid the sedation. Likewise,
when stopping the medication, the
dosage shou ld be ta i led down
gradually. Even then, many doctors
are hesistant to scale up to a high
420
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Table 5: Pharmacotherapy for panic disorder
Therapeutic agent Brand name
A.
B.
C.
D.
Benzodiazepines
1. Alprazolam
2, Clonazepam
Tricyclics
1. Imipramine
2, Clomipramine
Monoamine oxidase inhibitors
1. Phenelzine
2. Moclobemide
Selective serotonin re-uptake inhibitors
1. Fluoxetine
2. Fluvoxamine
3. Sertraline
4. Paroxetine
5. Citalopram ;
Xanax
Rivotril
Tofranil
Anafranil
Nardil
Aurorix
Prozac
Faverin
Zoloft
Seroxat
Cipram
Total daily dose
4 to 10 mg
2: to 5 mg
150 to 250 mg
150 to 250 mg
15 to 75 mg
150 to 600 mg
20 mg
50 mg
50 mg
20 mg
20 mg
d o s a g e and w o r r y a b o u t t he
p o s s i b i l i t y of drug dependency.
Therefore they can consider other
types of medications. The effects of
c lomipramine seemed better than
imipramine,13 and the SSRIs seemed
superior to the tricyclics because of
less s i d e - e f f e c t s . 1 4 A n y w a y ,
whichever medication is used, the
dosage should be titrated to a suitable
level, maintained for a period and
then tapered off ; w i th the total
duration usually lasting about a year.
However, l i t t le is known about the
long term efficacy of medications.
After the acute period, continued
therapy may be necessary, and acute
withdrawal of the medications may
be harmful . Continued treatment
with clonazepam,15 alprazolam16 or
i m i p r a m i n e ' 7 seemed to show
continued efficacy, but these studies
were uncontrolled and retrospective.
Judge et al18 found a high relapse rate
among patients switched to placebo
compared with continued paroxetine;
and recently, Michelson et al19 found
that c o n t i n u i n g treatment for 24
weeks with fluoxetine is better than
placebo.
Psychotherapy
Various psychological measures
h a v e been advoca ted such as
psychoanalysis or psycho-dynamic
psychotherapy. However, in recent
years, the most successful paradigm
is the use of cognitive-behavioural
therapy (CBT). Using this method,
the therapist together with the patient
try to identify the circumstances and
the common bodily sensations and
associated thoughts, and the previous
coping strategies (Table 6). The
definitive therapy consists of firstly
to replace f a u l t y t h i n k i n g with
adaptive ones or alternative explana-
tions, e.g. I will never faint, my heart
is normal, I can overcome this panic
attack, etc. Next, the patient has to
test them out by facing the panicky
situations (called exposure, either by
graded/systematic desensitization, or
by f looding) and to overcome the
faulty avoidant behaviour with more
appropriate response, e.g. stay in the
place and breathe slowly. Finally,
t h e r e s h o u l d a l so be r e l apse
prevention by recognizing the early
signs and restar t ing the cognitive
therapy again. Such therapy could be
conducted individually or in a group.
Drugs or psychotherapy
W h e t h e r d rug t h e r a p y o r
psychotherapy is superior in treating
panic disorder is controversial.20-22 It
ha s b e e n s u g g e s t e d t h a t a
combination of drug therapy with
psychotherapy is superior (Table 7).
Studies so far included imipramine,23
p h e n e l z i n e , 2 4 f l u v o x a m i n e , 2 5
paroxetine7 and busipirone.26 On the
other hand, Loerch et a l 2 7 had
recently found that CBT was highly
effective either in combination with
moclobemide (the new reversible
MAOI) or with placebo.
Miscellaneous measures
Others measures have been tried
with occasional success. One method
is the use of the b i o f e e d b a c k
machine. There is hypnosis therapy
which induces a trance-like state by
suggestion, and the patients are then
(Continued on page 423)
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Table 6: The construction of a dysfunctional thought diary
Date Situation
1 Jan 99 Crossing the road
2 Feb 99 Restaurant
Emotions (severity)
Anxious (moderate)
Sadness (severe)
Thoughts
Fear of collapse
I'll lose control
Outcome
Panic and faint
Panic and leave
Treatment Effectiveness Side-effects Drop-outs
Pharmacotherapy
1. Tricyclics
2. Benzodiazepines
3. SSRIs*
4. Beta-blockers
5. Short-term placebo
6. Long-term placebo
Psychotherapy
1. Cognitive-behavioural
2. Psychoanalysis
3. Biofeedback
High Moderate Moderate
High Mild Low
High Mild Low
Mild Low Moderate
Fair Nil Low
Low Nil High
High Nil Low
Low Nil High
Mild Nil Moderate
Onset Cost
Fair Low
Fast Fair
Fair High
Fast Low
Varies Nil?
Varies Nil?
Slow High
Very slow Very high
Fair Fair
* SSRIs = selective serotonic re-uptake inhibitors
told that there will be no more panic
at tacks . However, i ts benef i t is
usually short lasting.
Prognosis
About 50% of the patients show
recurrent or mild symptoms, with
30% recovering from the disorder.
However, 20% of the patients run a
chronic, severe course. In fact, those
with severe, prolonged periods of the
disorder, and continued avoidant or
other maladaptive behaviour, require
long-term management. •
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3. If untreated, there is a significant morbidity and sometimes mortality by suicide.
4. The causes are often bio-psycho-social, and treatment is effective using a similar bio-psycho-social approach.
5. At present, the selective serotonin re-uptake inhibitors are relatively safe and effective; while cognitive-
behavioural psychotherapy is the method of choice.
13. M o d i g n K, Wes tberg P. E r i k k s o n E.
Superiority of clomipramine over imipramine in
(he t r e a t m e n t of pan ic disorder: a placebo
controlled t r ia l . J Clin Psychopharmacol 1992;
12:251-261.
14. Nutt D. The role of SSRIs in anxie ty disorders.
Eur Neuropsychopharmacology 1995:5:260-
261.
15. Pollack MH, Tesar GE. Rosenbaum JR, et al.
Clonazepam in the treatment of panic disorder
and agoraphobia: a one-year follow-up. J Clin
Psychopharmacol 1986:6:302-304.
16. Nagy LM, Krys ta l JH. Woods SW, el al.
Clinica l and medication outcome after short-
term alprazolam and behavioral group treatment
in panic disorder: 2.5 year naturalistic follow-
up study. Arch Gen Psychiatry 1989:46:993-
999.
17. AronsonTA. A naturalistic study of imipramine
in panic disorder and agoraphobia. Am J
Psychiatry 1987:144:1014-1019.
18. Judge R, B u r n h a m DB, Steiner MX. et al.
Paroxetine long-term safety and efficacy in panic
disorder and prevention of relapse: a double-
b l i n d s t u d y , in Xth World Congress of
Psychiatry, Madrid, vol.2. New York: World
Psychiatr ic Association. 1996.
19. Michelson D. Pollack M. Lydiard KB, et al.
C o n t i n u i n g t rea tment of panic disorder af ter
acute response: randomised, placebo-controlled
trial with fluoxetine. Br J Psychiatry 1999:174:
213-218.
20. Black DW, Wesner R, Bowers W. et al. A
comparison of fluvoxamine. cognitive therapy,
and placebo in the treatment of panic disorder.
Arch Gen Psychiatry 1993:50:44-50.
21. Marks I, Swinson RP, Basoglu M. et al.
Alprazolam and exposure alone and combined
in panic disorder with agoraphobia: a controlled
study in London and Toronto. Br J Psychiatry
1993:162:776-787.
22. Clark DM. Salkovskis PM. Hackmann A, et al.
A comparison of cogni t ive therapy, applied
relaxation and imipramine in the treatment of
panic disorder. Br J Psychiatry 1994; 164:759-
769.
23. Mavissakalian M. Michelson L. Self-directed
in vivo exposure prac t ice in behaviora l and
pharmacological treatment of agoraphobia.
Behav Therapy 1983:14:506-519.
24. Sheehan DV, B a l l e n g e r J. J acobsen G.
Treatment of endogenous anxiety wi th phobic,
hysterical and hypochondriacal symptoms. Arch
Gen Psychiatry 1980;37:51 -59.
25. Cot t raux J, Note LD. Cungi C. et al. A
controlled study of cognitive behaviour therapy
with busipirone or placebo in panic disorder
with agoraphobia. Br J Psychiatry 1995:167:
635-641.
26. De Beurs E, van Dyck R, van Balkom AJLM,
et al. Assessing the cl inical significance of
outcome in agoraphobia research: a comparison
of two approaches. Behav Therapy I994;25:
147-158.
27. Loerch B, Graf-Morgenstern M, Hautzinger M,
et al. Randomised placebo-controlled trial of
moclobemide, cognitive-behavioural therapy and
the i r c o m b i n a t i o n in p a n i c disorder wi th
agoraphobia. Br J Psychiatry 1999; 174:205-
212.
424
